Fig. 2
RNS60 delays muscle weakness onset and paralysis and increases survival interval in C57BL/6-SOD1G93A mice. The treatment with RNS60 (300 μl/mouse/IP) every other day starting from the onset (hind limbs tremor and reduced abduction) a Kaplan-Meier curve showing the RNS60-induced delay (7 days) of the onset of muscle weakness based on the initial failure in the paw grip strength test for two consecutive time points. Log–rank Mantel–Cox test was done comparing NS (n = 21) vs RNS60 (n = 22) treated mice (p < 0.001). b Kaplan-Meier curve showing the RNS60-induced delay (7 days) of muscle paralysis, considered as the age at which the mice were no longer able to perform the grip strength test. Data were analyzed using the Log-rank test, p < 0.01. c Kaplan-Meier curve for survival showed an increase of about 10 days in mice treated with RNS60 (175.1 ± 2.8 days, mean ± SEM, n = 14 mice) compared to NS (164.7 ± 4.6 days, mean ± SEM, n = 13 mice) for the time at which 50% of the animals were euthanized. This increase was not statistically significant for the Log-rank test (p = 0.2544). d The survival interval, calculated from the symptom onset until the time at which the mice were euthanized, was increased by 17% by RNS60 (70.1 ± 2.9 days, mean ± SEM) compared to NS-treated mice (59.7 ± 4.6 days, mean ± SEM). The bar graph represents mean ± SEM. Difference between means was evaluated using non-parametric Mann Whitney test (p = 0.048)